Teitur Trophics has announced successful results from its phase 1 clinical trial of TT‑P34, a first‑in‑class peptide being developed for Parkinson’s disease. The study, conducted in healthy volunteers and patients with early‑stage Parkinson’s, showed the therapy was safe and well tolerated, with pharmacokinetic data confirming robust central nervous system exposure.
The company said the findings support plans to begin a phase II trial in 2027. TT‑P34 is designed to improve both mitochondrial and lysosomal function, targeting a pathway implicated in multiple neurodegenerative conditions.
Andreas Borta, Chief Medical Officer at Teitur Trophics, said: “These data show TT‑P34 – which is potentially a game‑changer not just for Parkinson’s disease but a range of other neurodegenerative diseases as well – has an excellent safety profile and is well‑tolerated, enters the brain and CNS as expected, and has excellent pharmacokinetics.” He added: “The biomarker data, which indicate engagement of the lysosomal pathway, are also highly encouraging.”
Simon Mølgaard, Co‑founder & Chief Executive Officer of Teitur Trophics, said: “These are remarkable results from our phase I clinical trial of TT‑P34 in healthy volunteers and patients with early‑stage Parkinson’s disease.” He added: “We are now fundraising for a Series B investment round ahead of our planned phase II study of TT‑P34 in Parkinson’s.”
The randomised, double‑blind, placebo‑controlled trial was carried out at the Centre for Human Drug Research in Leiden. It enrolled 55 healthy volunteers and 12 patients with early‑stage Parkinson’s. Once‑weekly subcutaneous dosing was safe at all levels tested, including alongside standard levodopa therapy.
Pharmacokinetic analysis confirmed TT‑P34 crosses the blood‑brain barrier, producing dose‑dependent CNS exposure. Weekly dosing is supported by the data.
The study also enabled development of a panel of cerebrospinal fluid biomarkers. Clear trends were observed over 50 days, with most Parkinson’s patients receiving TT‑P34 showing coordinated movement across multiple lysosomal proteins.
Teitur will present the phase 1 data at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul on 5 October.
